

Mary K Crow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6166977/publications.pdf>

Version: 2024-02-01

119
papers

15,531
citations

19657

61
h-index

23533

111
g-index

123
all docs

123
docs citations

123
times ranked

17254
citing authors

#	ARTICLE	IF	CITATIONS
1	Hydroxychloroquine and lupus flare: a good drug, but we need to do better. <i>Annals of the Rheumatic Diseases</i> , 2022, , annrhumdis-2021-221590.	0.9	3
2	When a Diagnosis Has No Name: Uncertainty and Opportunity. <i>ACR Open Rheumatology</i> , 2022, 4, 197-201.	2.1	3
3	Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity. <i>Clinical Immunology</i> , 2021, 223, 108649.	3.2	9
4	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 549-550.	5.6	1
5	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
6	Charles L Christian: model physician scientist and mentor. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 685-688.	0.9	3
7	Pregnancy and Rheumatic Disease: Experience at a Single Center in New York City During the COVID-19 Pandemic. <i>Arthritis Care and Research</i> , 2021, 73, 1004-1012.	3.4	4
8	The role of immunomodulatory medications in the treatment of COVID-19. <i>Current Opinion in Rheumatology</i> , 2021, 33, 431-445.	4.3	4
9	Preclinical Dose-Escalation Study of ZSJ-0228, a Polymeric Dexamethasone Prodrug, in the Treatment of Murine Lupus Nephritis. <i>Molecular Pharmaceutics</i> , 2021, 18, 4188-4197.	4.6	2
10	TREX1 variants in Sjogren's syndrome related lymphomagenesis. <i>Cytokine</i> , 2020, 132, 154781.	3.2	18
11	Reactivity of IgG With the p40 Protein Encoded by the Long Interspersed Nuclear Element 1 Retroelement: Comment on the Article by Carter et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 374-376.	5.6	5
12	Georgia Abortion Law and Our Commitment to Patients. <i>Arthritis and Rheumatology</i> , 2020, 72, 377-378.	5.6	1
13	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
14	Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. <i>Arthritis and Rheumatology</i> , 2020, 72, 1990-1997.	5.6	96
15	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
16	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
17	Type I interferons in host defence and inflammatory diseases. <i>Lupus Science and Medicine</i> , 2019, 6, e000336.	2.7	91
18	SLE: reconciling heterogeneity. <i>Lupus Science and Medicine</i> , 2019, 6, e000280.	2.7	23

#	ARTICLE	IF	CITATIONS
19	Interferon target-gene expression and epigenomic signatures in health and disease. <i>Nature Immunology</i> , 2019, 20, 1574-1583.	14.5	316
20	Mitochondrial DNA promotes autoimmunity. <i>Science</i> , 2019, 366, 1445-1446.	12.6	14
21	Cytokines in Lupus. , 2019, , 137-152.		2
22	Type I Interferons in Autoimmune Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 369-393.	22.4	179
23	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.9	36
24	Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	187
25	CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematosus. <i>Lancet, The</i> , 2018, 391, 1126-1127.	13.7	11
26	Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes. <i>Journal of Autoimmunity</i> , 2018, 88, 75-82.	6.5	65
27	MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome. <i>Scientific Reports</i> , 2017, 7, 7354.	3.3	28
28	Can Recombinant Granulocyte Colony Stimulating Factor Modulate Inflammatory Response in Extreme Low Gestational Age Newborns?: Effect of rhG-CSF on Cytokines in ELGAN. <i>Journal of Pediatric Infectious Diseases</i> , 2017, 12, 176-183.	0.2	0
29	07.08...Contribution of mthfr gene polymorphisms in primary sjögren's syndrome related lymphomagenesis. , 2017, , .		0
30	Etiology and Pathogenesis of Systemic Lupus Erythematosus. , 2017, , 1329-1344.		7
31	Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease. <i>Arthritis and Rheumatology</i> , 2016, 68, 2686-2696.	5.6	149
32	Reactive oxygen species induce virus-independent MAVS oligomerization in systemic lupus erythematosus. <i>Science Signaling</i> , 2016, 9, ra115.	3.6	127
33	Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2016, 172, 34-43.	3.2	19
34	Interferon $\hat{1}$ or $\hat{2}$: which is the culprit in autoimmune disease?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 439-440.	8.0	27
35	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16039.	30.5	816
36	Nilotinib (Tasigna,®) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 213.	3.5	83

#	ARTICLE	IF	CITATIONS
37	Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. <i>Journal of Autoimmunity</i> , 2015, 63, 47-58.	6.5	215
38	Interferon α and Angiogenic Dysregulation in Pregnant Lupus Patients Who Develop Preeclampsia. <i>Arthritis and Rheumatology</i> , 2015, 67, 977-987.	5.6	64
39	Targeting of type I interferon in systemic autoimmune diseases. <i>Translational Research</i> , 2015, 165, 296-305.	5.0	95
40	Identification of Candidate Predictors of Lupus Flare. <i>Transactions of the American Clinical and Climatological Association</i> , 2015, 126, 184-96.	0.5	1
41	Advances in understanding the role of type I interferons in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2014, 26, 467-474.	4.3	97
42	Type I Interferon in the Pathogenesis of Lupus. <i>Journal of Immunology</i> , 2014, 192, 5459-5468.	0.8	439
43	Measuring Interferon Alpha and Other Cytokines in SLE. <i>Methods in Molecular Biology</i> , 2014, 1134, 131-150.	0.9	4
44	Increased IFN α activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits. <i>Journal of Neuroimmunology</i> , 2013, 255, 85-91.	2.3	54
45	Proteomic Analysis of Synovial Fluid From the Osteoarthritic Knee: Comparison With Transcriptome Analyses of Joint Tissues. <i>Arthritis and Rheumatism</i> , 2013, 65, 981-992.	6.7	126
46	Increased Serum Type I Interferon Activity in Organ-Specific Autoimmune Disorders: Clinical, Imaging, and Serological Associations. <i>Frontiers in Immunology</i> , 2013, 4, 238.	4.8	17
47	Cytokines and Interferons in Lupus. , 2013, , 62-75.		1
48	Etiology and Pathogenesis of Systemic Lupus Erythematosus. , 2013, , 1269-1282.		3
49	IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 463-469.	0.9	127
50	Sarcoidosis Triggered by Interferon-Beta Treatment of Multiple Sclerosis: A Case Report and Focused Literature Review. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 206-212.	3.4	37
51	Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps. <i>Arthritis and Rheumatism</i> , 2012, 64, 982-992.	6.7	121
52	Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to Toll-like receptor 4 and Toll-like receptor 2 ligands via soluble CD14. <i>Arthritis and Rheumatism</i> , 2012, 64, 2268-2277.	6.7	83
53	Degos Disease. <i>American Journal of Clinical Pathology</i> , 2011, 135, 599-610.	0.7	91
54	Identification of a central role for complement in osteoarthritis. <i>Nature Medicine</i> , 2011, 17, 1674-1679.	30.7	470

#	ARTICLE	IF	CITATIONS
55	Interferon-Alpha in Systemic Lupus Erythematosus. , 2011, , 307-320.		0
56	A 26-year-old white man with a systemic lupus erythematosus flare and acute multiorgan ischemia: Vasculitis or thrombosis?. Arthritis Care and Research, 2011, 63, 766-774.	3.4	4
57	A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Molecular Medicine, 2011, 3, 142-152.	6.9	91
58	Synovial inflammation in patients undergoing arthroscopic meniscectomy: Molecular characterization and relationship to symptoms. Arthritis and Rheumatism, 2011, 63, 391-400.	6.7	213
59	Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Annals of the Rheumatic Diseases, 2011, 70, 1003-1009.	0.9	154
60	Soluble CD14 in synovial fluid from patients with OA and meniscal injury modulates the response of synovial fibroblasts to LPS. Annals of the Rheumatic Diseases, 2011, 70, A34-A35.	0.9	0
61	Autoimmune Disease Risk Variant of IFIH1 Is Associated with Increased Sensitivity to IFN- λ and Serologic Autoimmunity in Lupus Patients. Journal of Immunology, 2011, 187, 1298-1303.	0.8	143
62	Long interspersed nuclear elements (LINE-1): Potential triggers of systemic autoimmune disease. Autoimmunity, 2010, 43, 7-16.	2.6	76
63	Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon- λ ratios in rheumatoid arthritis patients: A post hoc analysis of a predominantly Hispanic cohort. Arthritis and Rheumatism, 2010, 62, 392-401.	6.7	77
64	Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis and Rheumatism, 2010, 62, 3607-3614.	6.7	123
65	Interferon-alpha: A Therapeutic Target in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2010, 36, 173-186.	1.9	59
66	Activation of the type I interferon pathway in primary Sjogren's syndrome. Journal of Autoimmunity, 2010, 35, 225-231.	6.5	165
67	Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. Brain, Behavior, and Immunity, 2010, 24, 1018-1024.	4.1	68
68	Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Research and Therapy, 2010, 12, R151.	3.5	103
69	Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Research and Therapy, 2010, 12, S5.	3.5	111
70	Activation of Mammalian Target of Rapamycin Controls the Loss of TCR α in Lupus T Cells through HRES-1/Rab4-Regulated Lysosomal Degradation. Journal of Immunology, 2009, 182, 2063-2073.	0.8	221
71	Cutting Edge: Autoimmune Disease Risk Variant of STAT4 Confers Increased Sensitivity to IFN- λ in Lupus Patients In Vivo. Journal of Immunology, 2009, 182, 34-38.	0.8	210
72	Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis and Rheumatism, 2009, 60, 22-29.	6.7	93

#	ARTICLE	IF	CITATIONS
73	Developments in the clinical understanding of lupus. <i>Arthritis Research and Therapy</i> , 2009, 11, 245.	3.5	36
74	Clinical applications of IFN- λ blockade in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 617-619.	0.3	0
75	Anticyclic citrullinated peptide antibody-negative rheumatoid arthritis: Clues to disease pathogenesis. <i>Current Rheumatology Reports</i> , 2008, 10, 165-167.	4.7	2
76	Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro- α positive mothers of children with neonatal lupus. <i>Arthritis and Rheumatism</i> , 2008, 58, 541-546.	6.7	84
77	Association of the IRF5 risk haplotype with high serum interferon- λ activity in systemic lupus erythematosus patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 2481-2487.	6.7	246
78	Age- and sex-related patterns of serum interferon- λ activity in lupus families. <i>Arthritis and Rheumatism</i> , 2008, 58, 2113-2119.	6.7	74
79	The <i>PTPN22</i> C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon- λ activity and low tumor necrosis factor λ levels in patients with lupus. <i>Arthritis and Rheumatism</i> , 2008, 58, 2818-2823.	6.7	82
80	Interferon-induced versus chemokine transcripts as lupus biomarkers. <i>Arthritis Research and Therapy</i> , 2008, 10, 126.	3.5	12
81	Collaboration, Genetic Associations, and Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2008, 358, 956-961.	27.0	86
82	Fast forward for systemic lupus erythematosus clinical trials. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 387-387.	3.2	1
83	Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?. <i>Current Opinion in Rheumatology</i> , 2008, 20, 565-572.	4.3	231
84	Activation of type I interferon in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 579-588.	3.0	16
85	Systemic Lupus Erythematosus Predicts Increased Left Ventricular Mass. <i>Circulation</i> , 2007, 116, 419-426.	1.6	69
86	Mentors and heroes: The foundation and future of rheumatology. <i>Arthritis and Rheumatism</i> , 2007, 56, 1037-1043.	6.7	2
87	Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 3412-3419.	6.7	169
88	Augmented interferon- λ pathway activation in patients with Sjögren's syndrome treated with etanercept. <i>Arthritis and Rheumatism</i> , 2007, 56, 3995-4004.	6.7	140
89	Toll-like receptor λ -dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. <i>Nature Immunology</i> , 2007, 8, 487-496.	14.5	1,210
90	Soluble Mediators as Therapeutic Targets in Systemic Lupus Erythematosus: Cytokines, Immunoglobulin Receptors, and the Complement System. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 103-119.	1.9	13

#	ARTICLE	IF	CITATIONS
91	Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. <i>Journal of Autoimmunity</i> , 2006, 26, 165-171.	6.5	122
92	Preclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2006, 144, 249.	3.9	241
93	Modification of accessory molecule signaling. <i>Seminars in Immunopathology</i> , 2006, 27, 409-424.	4.0	31
94	Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. <i>Arthritis and Rheumatism</i> , 2006, 54, 1906-1916.	6.7	293
95	Characterization of Human Complement Receptor Type 2 (CR2/CD21) as a Receptor for IFN- λ : A Potential Role in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2006, 177, 383-394.	0.8	70
96	Early Growth Response-1 Is Required for CD154 Transcription. <i>Journal of Immunology</i> , 2006, 176, 811-818.	0.8	26
97	Academic rheumatology: Not just a man's world. <i>Arthritis and Rheumatism</i> , 2005, 52, 694-696.	6.7	1
98	Activation of the interferon- λ pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. <i>Arthritis and Rheumatism</i> , 2005, 52, 1491-1503.	6.7	608
99	Interferon pathway activation in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2005, 7, 463-468.	4.7	48
100	Arterial Stiffness in Chronic Inflammatory Diseases. <i>Hypertension</i> , 2005, 46, 194-199.	2.7	269
101	Ongoing Immunoglobulin Class Switch DNA Recombination in Lupus B Cells: Analysis of Switch Regulatory Regions. <i>Autoimmunity</i> , 2004, 37, 431-443.	2.6	12
102	Measurement of Cytokines in Autoimmune Disease. , 2004, 102, 129-154.		10
103	Coordinate overexpression of interferon- λ -induced genes in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 3958-3967.	6.7	394
104	Costimulatory molecules and T-cell-B-cell interactions. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 175-191.	1.9	26
105	Interferon- λ in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2004, 16, 541-547.	4.3	124
106	Interferon- λ : A new target for therapy in systemic lupus erythematosus?. <i>Arthritis and Rheumatism</i> , 2003, 48, 2396-2401.	6.7	86
107	Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2003, 349, 2399-2406.	27.0	1,270
108	Microarray analysis of gene expression in lupus. <i>Arthritis Research</i> , 2003, 5, 279.	2.0	167

#	ARTICLE	IF	CITATIONS
109	Microarray Analysis of Interferon-regulated Genes in SLE. <i>Autoimmunity</i> , 2003, 36, 481-490.	2.6	251
110	Introduction Type I Interferon and Autoimmune Disease. <i>Autoimmunity</i> , 2003, 36, 445-446.	2.6	14
111	T Cell Proliferation Induced by Autologous Non-T Cells Is a Response to Apoptotic Cells Processed by Dendritic Cells. <i>Journal of Immunology</i> , 2002, 169, 1241-1250.	0.8	44
112	Functional properties of lymphocytes in idiopathic thrombocytopenic purpura. <i>Human Immunology</i> , 2001, 62, 1346-1355.	2.4	32
113	Regulation of CD40 ligand expression in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2001, 13, 361-369.	4.3	56
114	Induction of Fas Ligand-Mediated Apoptosis by Interferon- γ . <i>Clinical Immunology</i> , 2000, 95, 218-226.	3.2	59
115	Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. <i>Arthritis and Rheumatism</i> , 1999, 42, 871-881.	6.7	150
116	New Pieces to the SLE Cytokine Puzzle. <i>Clinical Immunology</i> , 1999, 91, 1-5.	3.2	23
117	Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. <i>Journal of Leukocyte Biology</i> , 1995, 58, 209-216.	3.3	203
118	A potential role for microbial superantigens in the pathogenesis of systemic autoimmune disease. <i>Arthritis and Rheumatism</i> , 1991, 34, 468-480.	6.7	145
119	Activated B lymphocytes: Stimulators of an augmented autologous mixed leukocyte reaction. <i>Cellular Immunology</i> , 1985, 90, 555-568.	3.0	26